- Home
- BRNS vs CPIX Comparison
BRNS vs CPIX Comparison
Compare BRNS & CPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRNS
- CPIX
- Stock Information
- Founded
- BRNS 2016
- CPIX 1999
- Country
- BRNS United Kingdom
- CPIX United States
- Employees
- BRNS N/A
- CPIX N/A
- Industry
- BRNS Biotechnology: Pharmaceutical Preparations
- CPIX Biotechnology: Pharmaceutical Preparations
- Sector
- BRNS Health Care
- CPIX Health Care
- Exchange
- BRNS Nasdaq
- CPIX Nasdaq
- Market Cap
- BRNS 36.0M
- CPIX 40.1M
- IPO Year
- BRNS 2021
- CPIX 2009
- Fundamental
- Price
- BRNS $1.05
- CPIX $3.06
- Analyst Decision
- BRNS Strong Buy
- CPIX
- Analyst Count
- BRNS 1
- CPIX 0
- Target Price
- BRNS $3.00
- CPIX N/A
- AVG Volume (30 Days)
- BRNS 16.3K
- CPIX 117.1K
- Earning Date
- BRNS 08-07-2025
- CPIX 08-05-2025
- Dividend Yield
- BRNS N/A
- CPIX N/A
- EPS Growth
- BRNS N/A
- CPIX N/A
- EPS
- BRNS N/A
- CPIX N/A
- Revenue
- BRNS $14,969,000.00
- CPIX $41,083,299.00
- Revenue This Year
- BRNS N/A
- CPIX N/A
- Revenue Next Year
- BRNS N/A
- CPIX N/A
- P/E Ratio
- BRNS N/A
- CPIX N/A
- Revenue Growth
- BRNS 4381.74
- CPIX 5.82
- 52 Week Low
- BRNS $0.64
- CPIX $1.04
- 52 Week High
- BRNS $1.58
- CPIX $7.25
- Technical
- Relative Strength Index (RSI)
- BRNS 57.55
- CPIX 36.79
- Support Level
- BRNS $0.90
- CPIX $3.00
- Resistance Level
- BRNS $1.05
- CPIX $3.76
- Average True Range (ATR)
- BRNS 0.06
- CPIX 0.53
- MACD
- BRNS 0.01
- CPIX -0.06
- Stochastic Oscillator
- BRNS 71.96
- CPIX 17.98
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.
About CPIX Cumberland Pharmaceuticals Inc.
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment which is specialty pharmaceutical products. The company's target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derived from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, Sancuso, Vaprisol and Vibativ.